We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to des... Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency. Show more
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results PR Newswire SAN DIEGO, Feb. 28, 2024 SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.49 | -1.40764148233 | 34.81 | 35.08 | 34.2237 | 314519 | 34.67018183 | CS |
4 | -0.68 | -1.94285714286 | 35 | 35.42 | 34.2237 | 440060 | 34.83366237 | CS |
12 | -3.33 | -8.84462151394 | 37.65 | 39.79 | 34.2237 | 508134 | 36.14277434 | CS |
26 | 17.14 | 99.7671711292 | 17.18 | 39.79 | 14.305 | 603593 | 32.37324391 | CS |
52 | 14.23 | 70.831259333 | 20.09 | 39.79 | 14.305 | 504417 | 28.12224828 | CS |
156 | 16.27 | 90.1385041551 | 18.05 | 47.9 | 7.67 | 415119 | 25.77990487 | CS |
260 | 14.62 | 74.2131979695 | 19.7 | 50.97 | 7.67 | 361233 | 25.87466418 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions